PDX Platform Expansion Champions Oncology’s core CTG PDX model platform, expanded recently with scalable Chem-Seq and Functional-Seq platforms as well as a 3D screening platform using HER2-positive PDXOs, signals growing capabilities for high-value translational studies and more robust preclinical decision support that can be packaged into premium CRO services for oncology sponsors.

Integrated Data Platform The development of an integrated platform centered on PDX models that combines patient tumors with molecular and clinical data positions Champions as a one-stop solution for biomarker discovery, drug sensitivity testing, and precision oncology workflows that can be marketed to pharma and biotech clients seeking end-to-end translational services.

Strategic Partnerships A broad Clinical Collaboration Network supplying CTG models, plus recent ventures with Turbine to merge multi-omic datasets and virtual lab capabilities, create cross-sell opportunities for bundled services across in vitro to in vivo testing, data integration, and computational screening for drug development pipelines.

Board & Leadership Momentum Appointment of additional board expertise and ongoing leadership engagement indicate strategic governance and growth ambitions, which can be leveraged to approach larger biotech and pharma firms looking for vetted translational partners and potential co-development arrangements.

Financial Health & Growth With revenue in the mid-range six figures to low hundreds of millions and positive recent earnings trends alongside ongoing funding, Champions demonstrates financial stability that can support expanded sales conversations around long-term collaborations, capacity expansion, and milestone-driven deals.